当前位置: 首页 >> 检索结果
21. Letter by Wang et al Regarding Article, "Bone Morphogenetic Protein 9 Protects Against Myocardial Infarction by Improving Lymphatic Drainage Function and Triggering DECR1-Mediated Mitochondrial Bioenergetics".23. Response by Murai et al to Letter Regarding Article, "Impact of Post-PCI Lipid Core Burden Index on Angiographic and Clinical Outcomes: Insights From NIRS-IVUS".
作者: Woohyeun Kim.;Hyungdon Kook.;Yonggu Lee.;Young-Hyo Lim.
来源: Circ Cardiovasc Imaging. 2025年e018586页 27. Dynamic Updating Strategies to Assess Hospital Performance of Surgical Aortic Valve Replacement.
作者: Jackie Pollack.;Wei Yang.;George J Arnaoutakis.;Michael J Kallan.;Stephen E Kimmel.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011608页
Prediction models determining expected outcomes are infrequently updated (ie, static), which may reduce accuracy and misclassify hospital performance over time. Dynamic models incorporate changes over time and may improve accuracy and fairness in hospital comparisons. This study evaluated whether dynamic updating, compared with a static model, altered hospital rankings and outlier detection among surgical aortic valve replacement patients.
29. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
作者: Samer Al Said.;Siddharth M Patel.;Robert P Giugliano.;David A Morrow.;Erica L Goodrich.;Sabina A Murphy.;Bruce Hug.;Sanobar Parkar.;Shih-Ann Chen.;Shaun G Goodman.;Boyoung Joung.;Robert G Kiss.;Wojciech Wojakowski.;Jeffrey I Weitz.;Dan Bloomfield.;Marc S Sabatine.;Christian T Ruff.
来源: Circulation. 2025年
Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized.
30. Response by Wang et al to Letter Regarding Article, "Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis".35. Cardiac-Targeted AAV5-S100A1 Gene Therapy Protects Against Adverse Remodeling and Contractile Dysfunction in Postischemic Hearts.
作者: Dorothea Kehr.;Janek Salatzki.;Birgit Seger.;Karl Varadi.;Jennifer Birkenstock.;Philipp Schlegel.;Erhe Gao.;Walter J Koch.;Hugo Katus.;Norbert Frey.;Johannes Riffel.;Florian André.;Karsten Peppel.;Andreas Jungmann.;Martin Busch.;Helga Pfannkuche.;Julia Ritterhoff.;Patrick Most.
来源: Circ Heart Fail. 2025年e012479页
Guided by long-term safety data for AAV5 (adeno-associated virus 5) in humans, our translational study investigated whether AAV5 effectively delivers genes to healthy and achieves therapeutic efficacy in dysfunctional human-sized hearts, using a clinically applicable mode of administration and vector dosages.
37. Skeletal Muscle Quantity Versus Quality in Heart Failure: Exercise Intolerance and Outcomes in Older Patients With HFpEF Are Related to Abnormal Skeletal Muscle Metabolism Rather Than Age-Related Skeletal Muscle Loss.
作者: Sabra C Lewsey.;T Jake Samuel.;Michael Schär.;Joevin Sourdon.;Joseph R Goldenberg.;Lisa R Yanek.;Shenghan Lai.;Angela M Steinberg.;Paul A Bottomley.;Gary Gerstenblith.;Robert G Weiss.
来源: Circ Heart Fail. 2025年e012512页
Heart failure with preserved ejection fraction (HFpEF) is a systemic process with contributions from peripheral factors, including skeletal muscle (SM). Age-associated SM loss and impaired energy metabolism occur without heart failure, but the relative importance of changes in SM quantity versus metabolic quality in patients with HFpEF for exercise intolerance (EI) or outcomes has not been studied. We hypothesized that EI and subsequent clinical outcomes across the adult lifespan in patients with HFpEF are related to impaired SM energy metabolism rather than age-associated SM loss.
38. Impact of Neighborhood Factors on Exercise Capacity in Children With Hypertrophic Cardiomyopathy.
作者: Imran R Masood.;Lei Wang.;Helen M Stanley.;Jonathan J Edwards.;Humera Ahmed.;Kimberly Y Lin.;Carol A Wittlieb-Weber.;Matthew J O'Connor.;Joseph W Rossano.;Shannon O'Malley.;Stephen M Paridon.;Vicky W Tam.;Jonathan B Edelson.
来源: Circ Heart Fail. 2025年e012501页
Restricting certain patients with hypertrophic cardiomyopathy (HCM) from exercise likely has negative cardiovascular effects and has not been shown to reduce the risk of sudden cardiac death. Promoting exercise in children with HCM is complex and requires knowledge of the environmental factors that impact exercise capacity in children with HCM.
40. Implementing Precision Medicine for Dilated Cardiomyopathy: Insights From the DCM Consortium.
作者: Elizabeth Jordan.;Hanyu Ni.;Patricia Parker.;Daniel D Kinnamon.;Anjali Owens.;Brian Lowes.;Chetan Shenoy.;Cindy M Martin.;Daniel P Judge.;Daniel P Fishbein.;Douglas Stoller.;Elina Minami.;Evan P Kransdorf.;Frank Smart.;Garrie J Haas.;Gordon S Huggins.;Gregory A Ewald.;Jamie Diamond.;Jane E Wilcox.;Javier Jimenez.;Jessica Wang.;Jose Tallaj.;Mark H Drazner.;Mark Hofmeyer.;Matthew T Wheeler.;Omar Wever Pinzon.;Palak Shah.;Stephen S Gottlieb.;Stuart Katz.;Supriya Shore.;W H Wilson Tang.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年e005078页 |